Skip to main content
Egyptian Journal of Medical Human Genetics
Fig. 1 | Egyptian Journal of Medical Human Genetics

Fig. 1

From: B-lymphocyte-activating factor is a potential biomarker associated with susceptibility to Graves’ disease in Iraqi women

Fig. 1

Column-bar plots of serum B-lymphocyte-activating factor (BAFF) levels: A Graves’ disease (GD) patients and controls (CTRL), B therapy groups (ND newly diagnosed, CMZ carbimazole, RAI radioactive iodine), C age at onset groups; D disease duration groups, E body mass index group (NOR normal-weight, O/O overweight/obese); and F vitamin D groups (INSFT insufficient, SFT sufficient). Columns indicates median, while bars represent interquartile range (IQR). Significance was assessed using Mann–Whitney U test (***p < 0.001; ns not significant). BAFF levels were significantly elevated in GD patients compared to CTRL (Plot A: 1525 [IQR: 1327–1840] vs. 689 [IQR: 585–807] pg/mL; p < 0.001). When BAFF levels were stratified by some characteristics of GD patients (Plots B, C, D, E and F), there was no significant difference in each stratum

Back to article page